For how we live.
A Danish stepped-wedge trial gave endoscopists automated feedback on their technique after every procedure. Adenoma detection rose from 43.4% to 48.6% — a different tool from real-time polyp AI.
A Lancet series covering 135 million person-years found the largest risk reductions in that range. Trials of isolated fibre supplements produce much smaller effects on much narrower outcomes.
US guidance recommends mammography from 40. A Canadian review of the same randomised evidence put the benefit at 0.27 fewer breast cancer deaths per 1,000 women aged 40-49 over ten years.
IARC put bacon in the same category as tobacco in 2015, which says how sure scientists are, not how dangerous it is. The attributable-death figures are three orders of magnitude apart.
Nous-209 targets 209 mutations shared across a whole class of tumours, so it can be manufactured in advance. What the trial has not yet shown is that anyone got less cancer.
A linked-registry cohort of New South Wales residents from 2001 to 2018 finds cancer risk in people with intellectual disability inverts with age — higher when young, lower after 50.
SCREESCO randomised Swedish 60-year-olds to colonoscopy, stool testing, or nothing. After a median 4.8 years, overall cancer incidence barely moved; the stage distribution did.
The EAGLE trial ran colonoscopy AI off-site over a network and aimed it at the lesions that matter. It reports a threefold gain in serrated lesions — in a field whose main US guideline recommends nothing.
A 13-year-old observational hypothesis finally got its randomised test. In ALASCCA, 160 mg of daily aspirin cut three-year recurrence from 14.1% to 7.7% in biomarker-selected patients.
Over 17.4 years, high ultra-processed food intake was linked to a 24% higher colorectal cancer risk overall — and a 58% higher risk for right-sided colon cancer specifically.